Checkpoint Therapeutics, Inc.

As of May 6, 2021, Checkpoint Therapeutics, Inc. is considered overvalued with a valuation downgrade to "does not qualify," despite a strong year-to-date return of 33.12%, while its long-term performance shows a significant decline of -79.91% over five years compared to the S&P 500's 96.61%.

As of May 6, 2021, Checkpoint Therapeutics, Inc. is considered overvalued with a significant downgrade in investment appeal due to high financial ratios and negative returns, despite a strong stock performance year-to-date.

As of April 14, 2025, Checkpoint Therapeutics, Inc. exhibits a bullish technical trend supported by strong indicators like a bullish MACD, moving averages, and Bollinger Bands, alongside positive On-Balance Volume, despite a neutral RSI.

As of March 2022, the management team of Checkpoint Therapeutics, Inc. includes Chairman Michael Weiss, CEO James Oliviero, and several independent directors: Dr. Lindsay Rosenwald, Christian Bechon, Scott Boilen, Neil Herskowitz, and Barry Salzman. They oversee the company's strategic direction and operations.

Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company focused on developing immune-enhanced combination treatments for solid tumor cancers. It has a market cap of approximately $370.71 million and reported a net profit of -$11 million as of March 2025.

As of May 29, Checkpoint Therapeutics, Inc. has a market capitalization of 370.71 million, with net sales of 0.04 million and a net profit of -56.50 million over the last four quarters. The balance sheet as of December 2024 shows shareholder's funds of -12.62 million and total assets of 7.47 million.